Business Model Breakdown
How Zevra Therapeutics Inc Makes Money
ZVRA
Market Cap
$589M
Annual Revenue
$107M
Profit Margin
78.2%
Employees
59
The Short Version
Zevra Therapeutics is a biopharmaceutical company that generates revenue by developing and commercializing specialty drugs for rare diseases, specifically Niemann-Pick Type C (NPC). Its core business revolves around the sale of MIPLYFFA (Arimoclomol), an FDA-approved prescription medication for NPC in the United States. Zevra leverages the orphan drug designation for MIPLYFFA, which grants market exclusivity and enables premium pricing due to the high unmet medical need and small patient population. The company manages clinical development, regulatory approval processes, manufacturing, and commercial distribution to bring these specialized therapies to patients.
Where the Revenue Comes From
MIPLYFFA (Arimoclomol) product sales (~82% of FY25 total revenue)
Asset monetization (e.g., sale of SDX portfolio, Priority Review Voucher - episodic)
Who buys: Patients diagnosed with Niemann-Pick Type C disease, prescribing physicians, specialized rare disease clinics, and potentially international healthcare systems or distributors.
Why It Works (Competitive Advantages)
- ✔Established first-mover advantage and physician familiarity for MIPLYFFA in US NPC market.
- ✔Orphan drug designation and related market exclusivity.
- ✔High switching costs for patients and providers in rare disease treatment.
Economic Moat: Narrow (Intangible Assets/IP (Orphan Drug Designation for MIPLYFFA/Arimoclomol), Switching Costs (physician prescribing habits, patient adherence to established treatment))
What Our Analysis Says
DVR Score as of April 22, 2026
Score Change Explanation: The previous analysis (2026-03-30, score 9.2/10) heavily weighted the 'significantly de-risked' future approval of Arimoclomol (Niemann-Pick Type C) with a mid-2026 PDUFA date and a 'strong pipeline'. However, updated real-time intelligence reveals material shifts: 1) Zevra has pivoted to a 'single-asset (MIPLYFFA) focus' by selling its SDX portfolio, significantly reducing pipeline breadth and increasing concentration risk. 2) MIPLYFFA (Arimoclomol) is *already commercial* in the US, with Q4 2025 revenue of $26.4M and >40% penetration. The 'mid-2026 PDUFA' as an initial approval catalyst is therefore moot or refers to an ex-US event not clearly articulated as a major near-term driver for the core investment thesis of a *new* drug's approval. This re-contextualization diminishes the 'de-risking' from a future approval. 3) Positively, the cash runway has extended from 2027 to 2029, bolstering financial health. 4) Negatively, significant insider selling by the CEO raises concerns. The increased single-asset risk and re-evaluation of the primary catalyst, despite improved cash runway, warrant a downward adjustment to reflect a higher risk profile for 10x growth.